The 16th National Conference on Geriatric Diseases and Nutritional Therapy was successfully held in Beijing from 2 to 4 June, organized by the Geriatric Nutrition Support Group of the Chinese Society for Parenteral and Enteral Nutrition and the China Association for the Promotion of International Exchange in Health Care,

The 86th National Pharmaceutical Trade Fair was held at Qingdao Expo City International Exhibition Center from May 9-11, 2023. As an influential professional event in the field of pharmaceutical preparations and health in China, this year's fair brought together more than 2,000 high-quality enterprises, with products covering more than 10 categories, including chemical drugs, biological drugs and OTC drugs, etc. Weixinkang exhibited 16 of its own products at this event.

he 11th National Conference on Oncology Nutrition, hosted by the Oncology Nutrition Committee of the China Anti-Cancer Association and organized by Beijing Jiatan Hospital of Capital Medical University, was held in Beijing from April 21 to 23.

From 20 to 22 April, the 9th National Congress of Pediatric Critical Care Physicians of the China Medical Association (CMCAP) was held at the Beiyuan Hotel in Beijing, hosted by the CMCAP and the Pediatric Critical Care Physicians Branch of the CMCAP.

On the evening of January 18, 2023, the National Health Insurance Bureau and the Ministry of Human Resources Social Security issued the Notice on the Issuance of the National Drug Catalogue for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (2022)> (Health Insurance Fa [2023] No. 5), in which Tibet Weixinkang Pharmaceutical Co.,Ltd. (hereinafter referred to as "the Company") has been included in the 2022 edition of the National Health Insurance Catalogue through medical insurance negotiations. This version of the National Health Insurance Catalogue will be officially implemented from March 1, 2023.

Recently, Inner Mongolia Baiyi Pharmaceutical Co., Ltd. , a wholly-owned subsidiary of Weixin Kang, received the "Certificate of Drug Registration" (Drug Approval No.: GYZZ H20223734) for Compound Amino Acid Injection (20AA), which was approved and issued by the State Drug Administration. The company has already started the pre-production preparation work and the launch of this product will bring new treatment options for patients.

August 18, 2021, Beijing Jingweixinkang Pharmaceutical Technology Development Co.,Ltd.

On December 3, 2019, the "10th Pharmaceutical Observer Emerging Forum" was held in Chongqing City, with nearly 1,000 participants including pharmaceutical-related government officials, pharmaceutical experts and scholars, entrepreneurs and pharmaceutical elites at large.